Mode
Text Size
Log in / Sign up
N/A N=25 Treatment

A Prospective, Multicenter All Comers Study of Phasix Mesh for Ventral or Incisional Hernia Repair

Ventral Hernia · Incisional Hernia

Enrolled (actual)
25
Serious AEs
24.0%
Results posted
May 2018
Primary outcome: Primary: Number of Participants With Hernia Recurrence — 0; 0; 0; 1 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Resorbable Mesh (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
C. R. Bard
Primary completion
Feb 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Hernia Recurrence
0; 0; 0; 1; 0; 0
SECONDARY
Number of Participants With Device Related Adverse Events
1
SECONDARY
Carolinas Comfort Scale (CCS) Total Score - Change From Baseline
-1.1
SECONDARY
Short Form (SF)-12 Version 2 - Physical Component Summary (Change From Baseline)
-5.3
SECONDARY
Short Form (SF)-12 Version 2 - Mental Component Summary (Change From Baseline)
-9.4
SECONDARY
Surgical Procedure Time
242.5
SECONDARY
Length of Hospital Stay
5.0
SECONDARY
Number of Study Related Post Operative Surgical Procedures
7
SECONDARY
Number of Study Related Post Operative New Hospital Admissions
5
SECONDARY
Number of Related Post-operative Visits Unrelated to Standard of Care
8
SECONDARY
Incidence of Seroma
1

Summary

Collect data on safety, performance, and effectiveness of Phasix Mesh in subject requiring primary ventral and incisional hernias.

Eligibility Criteria

Inclusion Criteria

  • Subject or subject's legally authorized representative must be willing to give written informed consent
  • Subject must be diagnosed with ventral or incisional hernia
  • Subject must be willing to undergo open ventral hernia repair and be able to undergo all other study procedures as outlined in this protocol.

Exclusion Criteria

  • Subject is an active smoker (if attempts to quit smoking within two weeks of surgery have failed and the patient is still an active smoker at the time of surgery).
  • Subject's hernia has recurred four or more times.
  • Subject's body mass index (BMI) >40 kg/m2.
  • Subject has peritonitis.
  • Subject is on or suspected to be placed on chemotherapy medications during any part of the study.
  • Chronic steroid use or immunosuppression drugs (> 6 months).
  • Subject has cirrhosis, and/or ascites.
  • Subject is American Society of Anesthesiology Class 4 or 5.
  • Subject is pregnant or planning to become pregnant during the course of the study.
  • Subject is known to be infected with human immunodeficiency virus (HIV).
  • Subject has a life expectancy of less than 2 years at the time of enrollment.
  • Subject has been treated with an investigational product in the past 30 days.
  • Subject is part of the site personnel directly involved with this study
  • Subject has a known allergy to tetracycline hydrochloride or kanamycin sulfate, the test device or its component materials.
  • Subject has any condition that in the opinion of the Investigator would preclude the use of the study device, or preclude the subject from completing the follow-up requirements
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02053168). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search